Presentations by Event

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases, ID Week, October 2017

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs, ID Week 2017

Program(s): durlobactam (etx2514)

Reversibility of β–lactamase inhibition by the broad-spectrum diazabicyclooctenone serine β–lactamase inhibitor ETX2514, ASM Microbe, June 2017

Adam Shapiro, ASM Microbe 2017

Program(s): durlobactam (etx2514)

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae, ASM Microbe, June 2017

Thomas Durand-Reville, ASM Microbe 2017

Program(s): etx0282

The Antibacterial Activity of Cefpodoxime and the Novel β–lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of β–lactamase-producing Enterobacteriaceae, ASM Microbe, June 2017

Sarah McLeod, ASM Microbe 2017

Program(s): etx0282

The Antibacterial Activity of Sulbactam and the Novel β–lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa, ASM Microbe, June 2017

Sarah McLeod, ASM Microbe 2017

Program(s): durlobactam (etx2514)

Cefpodoxime proxetil/ETX0282: A novel oral β-lactam/β-lactamase inhibitor combination to treat the emerging threat of multi-drug resistant Enterobacteriaceae, ASM Microbe, June 2017

John O’Donnell, ASM Microbe 2017

Program(s): etx0282

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo,

Alita Miller, ECCMID 2017

Program(s): durlobactam (etx2514)

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens, ECCMID, April 2017

Ruben Tommasi, ECCMID 2017

Program(s): durlobactam (etx2514)